Synoptical view

    Truffle investment
    € 25M

In summary

Symetis is specialized in minimally invasive cardiac valves.

This characteristic makes the technology very tolerant with regard to the positioning of the implant before its complete release. ACURATE valves are designed to treat patients with severe and symptomatic aortic valve stenosis, who are considered at high risk of surgical valve replacement. Instead of open-heart surgery, the replacement valve is delivered by a transcatheteral percutaneous administration system. The ACURATE platform is known for its ease of use when implanting valves. Pre-acquisition the company had a turnover of €60M and was number 3 after Edwards and Medtronic. The company was sold in 2017 to Boston Scientific for a total amount of $435 million



Next start-up